A prespecified cardiac magnetic resonance (CMR) substudy nested within the randomized CAMEO-SEMA trial evaluated cardiac structure and function in patients with obesity-related HFpEF. The study team reported that 49 participants completed paired CMR scans at baseline and at 52 weeks; 33 were randomized to semaglutide and 16 to placebo. Twenty-eight participants were female. Imaging was performed within one day of invasive exercise hemodynamic assessment to link structural and functional imaging with physiological measures.
The substudy specified a primary CMR endpoint and several secondary imaging outcomes. The authors reported the primary endpoint as change in LA reservoir strain. Other prespecified metrics included assessment of left ventricular filling dynamics indexed to chamber size, expressed as early filling rate divided by end-diastolic volume (eFR/EDV). The ClinicalTrials.gov identifier for the parent trial is NCT05371496. The abstract did not report dosing or other procedural details in the provided text.
Investigators reported a statistically significant improvement in left atrial reservoir function among participants treated with semaglutide versus placebo. The between-group difference in change in LA reservoir strain was +5.7% (95% CI, +0.3 to +9.7; P = 0.037). That increment indicates augmentation of atrial reservoir mechanics over 52 weeks in the treatment arm compared with placebo, as measured by CMR.
Left atrial performance is a direct determinant of left-sided filling and, by extension, exertional filling pressures. The authors linked the observed LA improvement to contemporaneous hemodynamic testing, suggesting atrial mechanics changed in parallel with cardiopulmonary physiology measured invasively.
The study team reported a sizable treatment effect on early diastolic filling when indexed to chamber volume. eFR/EDV increased by +0.64 s−1 (95% CI, +0.42 to +1.00; P < 0.0001) in the semaglutide arm compared with placebo. Short, direct interpretation: early filling improved relative to the ventricular size.
The authors also examined statistical associations between imaging changes and exercise hemodynamics. Improvements in LA reservoir strain were correlated with reductions in exercise pulmonary artery wedge pressure (PAWP) (r = −0.46, P < 0.001). The correlation between eFR/EDV improvement and exercise PAWP reduction was stronger (r = −0.65, P < 0.0001). These reported correlations link the imaging endpoints to invasive measures of diastolic load during exertion.
Beyond atrial indices and diastolic filling, the investigators reported structural remodeling with semaglutide. The treatment arm exhibited reduced left ventricular mass and restoration toward a more physiologic left ventricular geometry. The study team also observed improvements in right ventricular function and in biventricular myocardial mechanics, as measured by CMR-derived parameters described in the prespecified endpoints.
Those morphological and functional shifts were reported alongside the diastolic function benefits, creating a coherent pattern: chamber-level remodeling accompanied improvements in dynamic filling. The abstract provides the directional outcomes and statistical significance for primary endpoints; full methodological and quantitative details for each structural measure are available in the full paper and supplementary files cited by the authors.
The substudy was timed to pair CMR with invasive exercise hemodynamics, enabling direct correlation between imaging and physiology. Data indicated that changes in imaging-derived LA function and LV filling dynamics tracked with reductions in exercise PAWP, a key driver of exertional symptoms in HFpEF. The authors suggested these myocardial and chamber-level improvements could underlie previously reported hemodynamic benefits of semaglutide in obesity-related HFpEF.
This linkage—imaging changes correlated with invasive pressure reductions—strengthens mechanistic inference. The study team presented correlation coefficients and P values for those associations in the abstract, tying the CMR endpoints to clinically relevant physiological outcomes measured during exercise.
The authors acknowledge that this report is an early, peer-reviewed version of the manuscript; the version of record may be updated. The abstract did not include some procedural details such as semaglutide dosing, titration schedule, or granular CMR acquisition parameters; those items are reported in the full article and supplementary materials referenced by the authors. Source data files and supplementary PDFs were listed alongside the article for readers seeking detailed numerical results and methodology.
This substudy was relatively small (49 participants) and nested within a larger randomized trial; the abstract supplies group sizes and primary imaging outcomes but does not present all subgroup or multivariable analyses in the provided text. Readers should consult the full article and supplementary material for complete methods, expanded results, and technical parameters.
ClinicalTrials.gov registration is provided (NCT05371496). The authors made source data and supplementary documents available with the article, and peer review files are accessible as indicated in the publication record. The article version presented online is labeled as an early access, citable draft that may be replaced by the final version of record.